Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Shorts and low vol takedown
$AKTX Consent II trial scheduled to start May 14. Ask yourself why Capstone still not listed when ceo said ready to go?
Partnership imo.
https://clinicaltrials.gov/ct2/show/NCT03427060
Nice. Always had a hunch about those Irish fellas. You just confirmed it lol
1. What happens in 2 weeks?
2. Who is loaning you that kind of money?
Glta
Blast from the past. Next time, you trust that gut. Gl.
Thank you my friend. Will pull up chart tonight and shore up some Dough to bring to the table.
What’s the cash here
They always had that debt portfolio. Only recently announced a plan and partner to go covert it into revenue.
They had $158K cash on hand end of qtr. can’t sell shares fast enough to raise more seems like. All imo
https://investorshub.advfn.com/boards/m_read_msg.aspx?message_id=140114196
Luckily for Alexion, Brazil is a small market but this could result in similar situations in other areas where Alexion has a strong hold. Ceo of aktx has repeatedly made comments about Akari intending to undercut Alexion on pricing so this bodes well for aktx imo. Below remarks from most recent ER call.
Yes, another good question. I won't comment too much, it's Alexion's product and for them to discuss in more detail but obviously for those following their studies it was done non-inferior, their conclusion was non-inferior to Soliris and our result at 45 milligrams today is approximately equivalent to Soliris in terms of both approximate LDH numbers but most importantly reduction of transfusions and so you know 1210 is a good idea because it's less frequent dosing but it's still IV infusion and ours is subcu and we think ultimately the differentiation of subcu dosing in patient self-control is very important for patients. I think ours is a very, very good medicine in terms of reduction of transfusions on the other hand and I think the other you know important feature is that we have not yet formally addressed but we look forward to addressing is pricing, we know that the pricing is stable for Alexion and we think that there is room to discuss that pricing as we move forward.
Been following soliris patent situation in Brazil? $AKTX
Good for you oltimer. Hope this trade works for you
You must be very rich that you can keep adding. I might jump in here if other plays work for me next week. Gl
Call him if you’re vested here. Nice guy to talk to imo. If my thesis is right, he is working on licensing Coversin. News imminent imo. And $AKTX takes off bigly.
I don’t intend to marry him. Ego problem is fine with me as long as he can get the deals worked out.
What does Glenn do all day long?
Good point
$20 yet?
Sure but if he does indeed give you material info, you’re smart enough to not post here or else you could get in trouble too. Not worth it imo.
Ceo is not going to reveal any material information. Or else he will get lawsuits. Imo
Hit that sell button.
Thx bud. On otc best to just play charts and take singles imo than wait for home runs
He truly puts even some of the otc ceos to Shame
They’ll continue to use shareholders to fund their business like every other penny out there. New 52s and Lower lows coming imo. $DPWW
CEO here is a primary reason why I’m here. Solid guy. Google what he did at Zealand Pharma. Master at licensing ph II clear assets. Will do that again at Akari imo. See who he hired in Jan on board seat from JnJ. Yuggee
Not looking good.
Operating Activities. For the year ended December 31, 2017, we used net cash in operating activities of $1,040,533. When compared to the net loss of $14,649,962 for the year ended December 31, 2017, the majority of expenses were noncash.
Investing Activities. For the year ended December 31, 2017, cash of $125,000 was invested in leasehold improvements in Colorado compared to a substantial investment of $860,469 in 2016 for leasehold improvements in both Washington and Colorado.
Financing Activities . Net additional funds of $1,272,901 were provided mostly from new convertible stock.
They’re going after a big potential revenue pie with the NY partner (whom I think is the mystery investor). Even if they realize a small slice of the pie this will blow up to epic proportions. Just plain good business sense imo. Blockchain or anything else if that happens will be a bonus here. $LMFA
Correcto mundo
Told ya
One word. Dilution.
Tomorrow premarket be nice
Dip coming imo. Will load there
You thought those twitter rants came cheap?
$DPWW will be picking up more tomorrow.
$DPWW for 10¢ and higher imo
Lol. Similar tastes I think.
Insiders know the pot of gold they’re sitting on imo. Ray Prudo is not an idiot to own basically half the company himself. Glty $AKTX
Nice position there. You’ll make big bucks for sure. You don’t want to know how many I own